par Agathe Masson | Déc 17, 2024 | NCD Case Studies, NCD Partnerships, Actualités
Following the agreement on a new licensing model between the Medicines Patent Pool (MPP) & Novartis in collaboration with the ATOM Coalition, generic, quality-assured nilotinib is now available on NCDconnect! This initiative is crucial in making lifesaving...
par Agathe Masson | Déc 9, 2024 | Access to Care, NCD Solutions, Actualités
Sickle Cell Disease (SCD) is a genetic blood disorder that affects millions of people worldwide. Between 2010 and 2050, an estimated 14 million babies will be affected globally, with the vast majority born in low- and middle-income countries (LMICs). This staggering...
par Agathe Masson | Nov 19, 2024 | Healthcare Systems, NCD Policy, Actualités
“Localisation.” It’s a term we’ve heard frequently in recent years, but not without its critics—and perhaps rightly so. Many argue that “localisation” doesn’t fully capture the essence of legitimising communities to lead their own health solutions, often implying a...
par Agathe Masson | Fév 5, 2024 | Access to Care, NCD Partnerships, Actualités
IDA Foundation and the Access to Oncology Medicines (ATOM) Coalition are happy to announce their strategic partnership. Following World Cancer Day’s theme ‘Close the Care Gap’, this collaboration marks a significant step toward addressing the challenges of...
par Callie Weber | Jan 8, 2024 | Access to Care, NCD Policy, Actualités
Counterfeit and substandard medicine trafficking is one of the world’s fastest-growing and highest-value criminal enterprises. Analysts estimate the global counterfeit market to be worth between US$200 and $432 billion. Since the issue first came to light in a 2003...
